Clinical Trial

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Study acronym: ASCENT-GYN-01

Active, Not Recruiting Phase 3

Summary

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Protocol Amendment History 15 amendments

This ClinicalTrials.gov record has been amended 15 times since 2024-06-27; most recent amendment 2026-01-13.

Status change: Recruiting → Active, Not Recruiting 2026-01-13

Status change: Not Yet Recruiting → Recruiting 2024-09-23

Trial Details

NCT Number	NCT06486441
Lead Sponsor	Gilead Sciences Collaborators: GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group
Conditions	Endometrial Cancer
Enrollment	640 participants
Start Date	2024-08-28
Primary Completion	2029-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-29